{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:50:55Z","timestamp":1791928255742,"version":"4.3.4"},"reference-count":22,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n High-risk subsolid pulmonary nodules, especially mixed ground-glass nodules, can represent precancerous or early-stage lung adenocarcinoma spectrum lesions. Standard management relies mainly on risk stratification, repeated thin-slice computed tomography, and invasive diagnosis or surgery when progression suggests malignancy. Safe adjunctive pharmacologic options to reduce nodule progression remain limited. Yifei Sanjie Pill (YFSJ) is an 8-herb traditional Chinese medicine formula that has been previously studied as an adjunctive treatment for non\u2013small cell lung cancer. However, its effect on high-risk pulmonary nodules\u2014a distinct clinical condition\u2014has not yet been investigated.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This protocol describes a multicenter randomized trial evaluating the efficacy, safety, and exploratory mechanisms of YFSJ for preventing high-risk pulmonary nodule progression.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Adults aged 18 to 80 years with single or multiple mixed ground-glass nodules measuring \u22648 mm will be randomized in a 1:1 ratio to receive YFSJ optimized formula granules or matched placebo granules, 2 packets twice daily for 6 months. Both groups will receive guideline-based computed tomography surveillance and any clinically indicated standard diagnostic or therapeutic care. The primary outcome is the 2-year pulmonary nodule progression rate, defined as an increase in the lesion\u2019s longest diameter of \u22652 mm, an increase in the solid component of \u22651 mm, or the appearance of a new solid component. Secondary outcomes include lung cancer detection rate, surgery rate, 6-month nodule size and volume change, artificial intelligence\u2013based malignancy risk index, traditional Chinese medicine symptom score, Hospital Anxiety and Depression Scale (HADS) score, Pittsburgh Sleep Quality Index (PSQI) score, safety indicators, and exploratory plasma biomarkers. The primary analysis will use the full analysis set, Kaplan-Meier estimates, log-rank testing, and Cox regression adjusted for center and key covariates; repeated outcomes will be analyzed using mixed-effects models.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study was funded in 2022 and approved by the Research Ethics Committee of the First Affiliated Hospital of Guangzhou University of Chinese Medicine (K-2022\u2010131-XZ-01). Recruitment started in June 2023 and was scheduled for completion in December 2025. As of April 2026, a total of 589 participants have completed randomization. The final 2-year follow-up is scheduled for December 2027. Database lock and primary analysis are planned for early 2028, and submission of the first results is expected in spring or summer 2028.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This trial will determine whether adding YFSJ to guideline-based surveillance can reduce high-risk pulmonary nodule progression and provide mechanistic evidence for integrative early lung cancer prevention.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/78534","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T20:41:22Z","timestamp":1784148082000},"page":"e78534-e78534","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Study on the Prevention of High-Risk Pulmonary Nodule Progression With Yifei Sanjie Pill: Protocol for a Multicenter Randomized Controlled Trial"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-2915","authenticated-orcid":false,"given":"Bo","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5507-3499","authenticated-orcid":false,"given":"Jietao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9579-5181","authenticated-orcid":false,"given":"Jingrui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4096-0607","authenticated-orcid":false,"given":"Zhiqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2189-423X","authenticated-orcid":false,"given":"Minyi","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5618-6439","authenticated-orcid":false,"given":"Yanlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1616-5400","authenticated-orcid":false,"given":"Xiangjun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0991-672X","authenticated-orcid":false,"given":"Lingling","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0436-4394","authenticated-orcid":false,"given":"Lizhu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"12","key":"R1","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data","volume":"8","author":"Qi","journal-title":"Lancet Public Health"},{"issue":"1","key":"R2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25010028","article-title":"Glycomic signatures of plasma IgG improve preoperative prediction of the invasiveness of small lung nodules","volume":"25","author":"Zou","journal-title":"Molecules"},{"issue":"10","key":"R3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1001\/jama.2021.0377","article-title":"Screening for lung cancer with low-dose computed tomography: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"325","author":"Jonas","journal-title":"JAMA"},{"issue":"3","key":"R4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/jama.2021.24287","article-title":"Evaluating the patient with a pulmonary nodule: a review","volume":"327","author":"Mazzone","journal-title":"JAMA"},{"issue":"1","key":"R5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0002","article-title":"NCCN Guidelines\u00ae insights: lung cancer screening, version 1.2025","volume":"23","author":"Wood","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"R6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1148\/radiol.2017161659","article-title":"Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017","volume":"284","author":"MacMahon","journal-title":"Radiology"},{"issue":"4","key":"R7","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.chest.2024.09.037","article-title":"The growth of screening-detected pure ground-glass nodules following 10 years of stability","volume":"167","author":"Kim","journal-title":"Chest"},{"issue":"1","key":"R8","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01904-6","article-title":"The diagnosis and management of multiple ground-glass nodules in the lung","volume":"29","author":"Li","journal-title":"Eur J Med Res"},{"issue":"4","key":"R9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.4103\/jcrt.jcrt_563_24","article-title":"Expert consensus on the multidisciplinary diagnosis and treatment of multiple ground glass nodule-like lung cancer (2024 Edition)","volume":"20","author":"Liu","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"R10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1037\/a0035730","article-title":"Biobehavioral approaches to cancer progression and survival: mechanisms and interventions","volume":"70","author":"Lutgendorf","journal-title":"Am Psychol"},{"issue":"3","key":"R11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.21037\/jtd-21-1423","article-title":"Should psychological distress be listed as a surgical indication for indeterminate pulmonary nodules: protocol for a prospective cohort study in real-world settings","volume":"14","author":"Zhuang","journal-title":"J Thorac Dis"},{"issue":"3","key":"R12","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1080\/21655979.2022.2037372","article-title":"Quercitrin restrains the growth and invasion of lung adenocarcinoma cells by regulating gap junction protein beta 2","volume":"13","author":"Li","journal-title":"Bioengineered"},{"issue":"5","key":"R13","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.21037\/jtd-23-1492","article-title":"Network pharmacology to explore the mechanism of traditional Chinese medicine in the treatment of ground glass nodules","volume":"16","author":"Wang","journal-title":"J Thorac Dis"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2357616","article-title":"Pills alleviate chemotherapy-related fatigue by reducing skeletal muscle injury and inhibiting tumor growth in lung cancer mice","volume":"2022","author":"Wu","journal-title":"Evid Based Complement Alternat Med"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1177\/15347354221151147","article-title":"Yifei Sanjie formula or placebo with anlotinib as second-line or above treatment for metastatic non-small-cell lung cancer: study protocol for a double-blind, placebo-controlled randomized pilot study","volume":"22","author":"Chen","journal-title":"Integr Cancer Ther"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.851554","article-title":"Deciphering the effects and mechanisms of Yi-Fei-San-Jie-Pill on non-small cell lung cancer with integrating network target analysis and experimental validation","volume":"13","author":"Yang","journal-title":"Front Pharmacol"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154843","article-title":"Identification of the active compounds in the Yi-Fei-San-Jie formula using a comprehensive strategy based on cell extraction\/UPLC-MS\/MS, network pharmacology, and molecular biology techniques","volume":"115","author":"Hu","journal-title":"Phytomedicine"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.156175","article-title":"Yi-Fei-San-Jie Chinese medicine formula reverses immune escape by regulating deoxycholic acid metabolism to inhibit TGR5\/STAT3\/PD-L1 axis in lung cancer","volume":"135","author":"Chen","journal-title":"Phytomedicine"},{"issue":"3","key":"R19","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00330-022-09138-y","article-title":"The long-term course of subsolid nodules and predictors of interval growth on chest CT: a systematic review and meta-analysis","volume":"33","author":"Wu","journal-title":"Eur Radiol"},{"issue":"10","key":"R20","first-page":"1183","volume":"25","author":"Li","journal-title":"Chin J Evid Based Med"},{"issue":"6","key":"R21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The Hospital Anxiety and Depression Scale","volume":"67","author":"Zigmond","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"R22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","journal-title":"Psychiatry Res"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e78534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:26:52Z","timestamp":1785536812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e78534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":22,"URL":"https:\/\/doi.org\/10.2196\/78534","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"v15i12e78534"}}